#1 Clinical Trials Search in Europe

Belzutifan

Belzutifan, also known as MK-6482 or WELIREG, is an innovative drug being studied in clinical trials for the treatment of various types of cancer. This article explores the use of Belzutifan in clinical trials, its potential benefits, and its impact on patients with advanced solid tumors, particularly renal cell carcinoma and Von Hippel-Lindau disease-associated cancers.

Table of Contents

What is Belzutifan?

Belzutifan is a promising new medication being studied for the treatment of various types of cancer. It is also known by several other names, including MK-6482, PT2977, and WELIREG™[1]. This drug is part of a class of medications called Hypoxia-Inducible Factor-2 alpha (HIF-2α) inhibitors[2].

How Does Belzutifan Work?

Belzutifan works by targeting a specific protein in cancer cells called HIF-2α. This protein plays a crucial role in how cancer cells respond to low oxygen levels, a condition known as hypoxia. By inhibiting HIF-2α, belzutifan can potentially slow down or stop the growth of cancer cells[1].

In simpler terms, cancer cells often thrive in low-oxygen environments. Belzutifan disrupts this process, making it harder for cancer cells to survive and grow.

Conditions Treated with Belzutifan

Belzutifan is being studied for the treatment of several types of cancer, including:

  • Renal Cell Carcinoma (RCC): This is a type of kidney cancer. Belzutifan has shown promise in treating advanced clear cell renal cell carcinoma (ccRCC)[3].
  • Von Hippel-Lindau (VHL) Disease: This is a rare genetic condition that causes tumors to grow in various parts of the body. Belzutifan has been studied specifically for VHL-associated renal cell carcinoma[4].
  • Pheochromocytoma/Paraganglioma (PPGL): These are rare tumors that develop in certain nerve cells[5].
  • Pancreatic Neuroendocrine Tumors (pNET): These are uncommon tumors that occur in the hormone-producing cells of the pancreas[5].
  • Advanced Gastrointestinal Stromal Tumors (GIST)[5].
  • Other solid tumors with HIF-2α related genetic alterations[5].

Clinical Trials and Research

Belzutifan is currently being studied in various clinical trials to determine its effectiveness and safety. These trials are investigating different aspects of the drug, including:

  • Optimal dosing: Researchers are studying different doses to find the most effective and safe amount for patients[3].
  • Combination therapies: Some trials are looking at how belzutifan works when combined with other cancer treatments[6].
  • Effectiveness in different types of cancer: Multiple studies are exploring how well belzutifan works for various cancer types[5].
  • Long-term effects: Researchers are monitoring patients to understand the long-term benefits and potential side effects of belzutifan[4].

Dosage and Administration

Belzutifan is typically taken orally in tablet form. The dosage can vary depending on the specific condition being treated and the individual patient. Some common dosages being studied include:

  • 120 mg once daily[4]
  • 160 mg twice daily[3]
  • 200 mg three times daily[3]

It’s important to note that these dosages are still being studied, and the optimal dose may vary for different patients and conditions. Always follow your doctor’s instructions regarding medication dosage and administration.

Potential Side Effects

As with any medication, belzutifan may cause side effects. Common side effects reported in clinical trials include:

  • Anemia (low red blood cell count)
  • Fatigue
  • Nausea
  • Dizziness
  • Headache

More serious side effects may occur, but they are less common. It’s important to report any unusual symptoms to your healthcare provider promptly[5].

Future Prospects

Belzutifan represents a new approach to cancer treatment by targeting the HIF-2α pathway. While it’s still in the research phase for many conditions, early results have been promising, particularly for certain types of kidney cancer and VHL-associated tumors.

As research continues, we may see belzutifan approved for more types of cancer and potentially in combination with other treatments. The ongoing clinical trials will provide more information about its long-term effectiveness and safety[6].

If you’re interested in learning more about belzutifan or participating in a clinical trial, speak with your oncologist or healthcare provider. They can provide more information specific to your condition and help determine if belzutifan might be an appropriate treatment option for you.

Aspect Details
Drug Name Belzutifan (MK-6482, PT2977, WELIREG)
Drug Class Hypoxia-Inducible Factor-2 alpha (HIF-2α) inhibitor
Administration Oral tablets, various dosages (e.g., 120 mg, 160 mg)
Main Cancer Types Studied Advanced solid tumors, clear cell renal cell carcinoma (ccRCC), Von Hippel-Lindau (VHL) disease-associated tumors
Key Outcome Measures Objective Response Rate (ORR), Progression-Free Survival (PFS), Duration of Response (DOR)
Safety Monitoring Adverse events (AEs), physical examinations, vital signs, ECGs, laboratory studies
Trial Phases Phase 1 and Phase 2 studies
Special Populations Patients with renal impairment, hepatic impairment

FAQ

  • What is Belzutifan and how does it work? Belzutifan is a Hypoxia-Inducible Factor-2 alpha (HIF-2α) inhibitor. It works by blocking the function of the HIF-2α transcription factor, which impairs hypoxic signaling in cancer cells and stops the transcription of genes involved in cancer growth.
  • What types of cancer is Belzutifan being studied for? Belzutifan is being studied for various types of cancer, including advanced solid tumors, clear cell renal cell carcinoma (ccRCC), Von Hippel-Lindau (VHL) disease-associated tumors, pancreatic neuroendocrine tumors, and glioblastoma.
  • What are the main objectives of the clinical trials involving Belzutifan? The main objectives of these trials include determining the maximum tolerated dose (MTD), evaluating the safety and efficacy of the drug, assessing objective response rates (ORR), and studying progression-free survival (PFS) in patients with various types of cancer.
  • How is Belzutifan administered to patients in clinical trials? Belzutifan is typically administered orally in tablet form. The dosage and frequency may vary depending on the specific trial, but common doses include 120 mg or 160 mg taken once or multiple times daily.
  • What are some potential side effects of Belzutifan? While specific side effects are not detailed in the provided information, clinical trials are closely monitoring for adverse events (AEs). Patients are regularly assessed through physical examinations, vital sign measurements, electrocardiograms (ECGs), and laboratory studies to ensure safety.

Ongoing Clinical Trials on Belzutifan

  • Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

    Recruiting

    1 1 1
    Investigated drugs:
    Czechia Denmark France Germany Greece Italy +3

  • A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium Czechia Denmark Finland France Germany +4

  • A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Croatia Czechia Denmark France +6

  • Phase 2 Evaluation of Belzutifan Monotherapy in Advanced Pheochromocytoma, Paraganglioma, pNET, VHL-Associated Tumors, wt GIST, and HIF-2α Altered Solid Tumors

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark France Germany Hungary Italy The Netherlands +4

  • Study of XL092 and belzutifan combination therapy in people with clear cell kidney cancer who had disease return during or after immunotherapy treatment

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Poland Spain

  • Study of Pembrolizumab, Vibostolimab, and Belzutifan for Patients with Metastatic Castration-Resistant Prostate Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Denmark Finland France Germany Ireland +5

  • A study of pembrolizumab, belzutifan, and lenvatinib before main treatment in patients with localized kidney cancer

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Spain

  • Study of Pembrolizumab, Lenvatinib, and Belzutifan for Patients with Renal Cell Carcinoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Hungary The Netherlands Poland Spain

  • Study of Belzutifan with Lenvatinib versus Cabozantinib in Adults with Advanced Renal Cell Carcinoma Who Have Previously Received Anti-PD-1/L1 Treatment

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Finland France Germany +7

  • Study of Belzutifan and Palbociclib for Patients with Advanced Renal Cell Carcinoma

    Not recruiting

    1 1 1
    Investigated drugs:
    France Germany Italy Poland Spain Sweden

Glossary

  • Hypoxia-Inducible Factor-2 alpha (HIF-2α): A transcription factor involved in the body's response to low oxygen levels. In cancer, it can promote tumor growth and survival.
  • Clear Cell Renal Cell Carcinoma (ccRCC): A type of kidney cancer that is characterized by clear cells when viewed under a microscope.
  • Von Hippel-Lindau (VHL) Disease: A rare genetic disorder that causes tumors and cysts to grow in various parts of the body, including the kidneys, brain, and spine.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that does not cause unacceptable side effects.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors version 1.1, a set of rules used to measure how well a cancer patient responds to treatment.
  • Blinded Independent Central Review (BICR): A method of assessing treatment outcomes where independent experts review patient data without knowing which treatment was given.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References